MedPath
Found 15 clinical trials|View Analysis
Sort by:

Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Phase 2
Suspended
Conditions
Mantle Cell Lymphoma
Interventions
Biological: Obinutuzumab
Biological: Glofitamab
Drug: Pirtobrutinib
Procedure: Tumor Imaging
Procedure: Biospecimen Collection
Device: ClonoSeq Assay
Procedure: Bone Marrow Biopsy
First Posted Date
2024-02-12
Last Posted Date
2024-11-19
Lead Sponsor
C. Babis Andreadis
Target Recruit Count
30
Registration Number
NCT06252675
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

A Study of Tumor Imaging With Multispectral Optoacoustic Tomography

Active, not recruiting
Conditions
Breast Cancer
Melanoma
Interventions
Diagnostic Test: Multispectral Optoacoustic Tomography Imaging
First Posted Date
2022-08-04
Last Posted Date
2024-08-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
12
Registration Number
NCT05488483
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Consent only ), Montvale, New Jersey, United States

🇩🇪

Helmholtz Institute (Data Analysis Only), Munich, Germany

🇺🇸

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only), Commack, New York, United States

and more 1 locations

Improvement of the Operative Outcome in Patients With Primary VEGF + Unifocal Breast Cancer or DCIS Through the Intraoperative Visualization of the Tumor Using Molecular Imaging and Bevacizumab-IRDye-800CW

Phase 2
Withdrawn
Conditions
Breast Cancer
Interventions
Drug: Bevacizumab-IRDye800CW
First Posted Date
2022-05-04
Last Posted Date
2022-05-04
Lead Sponsor
Technical University of Munich
Registration Number
NCT05359874

Superb Microvascular Intraocular Tumor Imaging Study (SMITIS)

Not Applicable
Completed
Conditions
Ocular Tumor
Interventions
Diagnostic Test: Doppler technology
First Posted Date
2021-09-21
Last Posted Date
2024-10-21
Lead Sponsor
Centre Hospitalier Universitaire de Nice
Target Recruit Count
22
Registration Number
NCT05051384
Locations
🇫🇷

CHU de Nice, Nice, France

Low Dose ICG for Biliary Tract and Tumor Imaging

Phase 2
Completed
Conditions
Cholecystitis
Hepatocellular Carcinoma
Liver Metastases
Interventions
Drug: Indocyanine green
Device: PINPOINT Endoscopic Fluorescence
First Posted Date
2021-06-28
Last Posted Date
2023-08-30
Lead Sponsor
University of Florida
Target Recruit Count
60
Registration Number
NCT04942665
Locations
🇺🇸

University of Florida Health Shands, Gainesville, Florida, United States

Multicentric Bone Tumor Imaging Report and Data System

Completed
Conditions
Bone Neoplasm
Interventions
Diagnostic Test: Radiographs
First Posted Date
2021-05-12
Last Posted Date
2023-06-06
Lead Sponsor
Central Hospital, Nancy, France
Target Recruit Count
1100
Registration Number
NCT04884048
Locations
🇫🇷

Chu Bordeaux, Bordeaux, France

🇫🇷

Hôpital de Purpan - CHU Toulouse, Toulouse, France

🇫🇷

CHRU Besançon, Besançon, France

and more 6 locations

Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging

Early Phase 1
Conditions
Neoplasms
Neoplasms Malignant
Interventions
Drug: 18F-LY3546117 Injection
Procedure: PET Scan
First Posted Date
2021-01-25
Last Posted Date
2022-04-25
Lead Sponsor
Avid Radiopharmaceuticals
Target Recruit Count
30
Registration Number
NCT04721756
Locations
🇦🇺

Olivia Newton-John Cancer Institute and Austin Health, Heidelberg, Victoria, Australia

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Diagnostic Test: Tumor Imaging
Procedure: Tumor Tissue Collection
Procedure: Blood Sample Collection
First Posted Date
2019-11-18
Last Posted Date
2024-12-02
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
1065
Registration Number
NCT04165798
Locations
🇺🇸

Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona, United States

🇺🇸

City of Hope ( Site 0014), Duarte, California, United States

🇺🇸

UCSF Medical Center at Mission Bay ( Site 0007), San Francisco, California, United States

and more 36 locations

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer

Phase 2
Completed
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation: Zr-89 labelled durvalumab PET/CT
Drug: Durvalumab (MEDI4736)
First Posted Date
2019-02-25
Last Posted Date
2022-12-07
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
20
Registration Number
NCT03853187
Locations
🇳🇱

Radboud University Medical Center, Nijmegen, Netherlands

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Phase 2
Terminated
Conditions
Metastatic Pancreatic Cancer
Interventions
Diagnostic Test: Safety Laboratories
Other: AE Assessment
Other: Physical Exam
Other: Concomitant Medication Review
Diagnostic Test: Tumor Imaging
Drug: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Drug: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
Drug: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
First Posted Date
2018-10-22
Last Posted Date
2023-10-18
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
1
Registration Number
NCT03714555
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath